JenaValve Appoints Dr. Duane Pinto as Chief Medical Officer

October 24, 2022—JenaValve Technology, Inc. announced that Duane Pinto, MD, has been appointed as Chief Medical Officer.

According to the company, Dr. Pinto has more than 20 years of experience performing complex coronary, structural, and peripheral vascular procedures with and without circulatory assistance.

Before joining JenaValve, Dr. Pinto was an associate professor of Medicine at Harvard Medical School and served as the Chief of the Interventional Cardiology section at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He is also a trained proctor for the newest transcatheter valves and invited around the world to advise and perform interventional cardiology procedures.

He has published more than 100 original manuscripts, case reports, reviews, editorials, and book chapters on a wide variety of topics and studies, including outcomes and economic analyses for acute myocardial infarction and unstable angina. He has authored numerous device trials for both coronary and peripheral circulations. In addition, Dr. Pinto serves as a manuscript reviewer and is member of the editorial boards of multiple leading journals.

In the company’s press release, Dr. Pinto stated, “I am excited to join an innovative organization that is incredibly focused and dedicated to addressing unmet patient needs in the structural heart space. I look forward to expanding on the great work the team has already done.”

John Kilcoyne, Chief Executive Officer of JenaValve, commented in the company’s press release, “We are incredibly pleased to welcome Dr. Pinto to the JenaValve team. Dr. Pinto’s vast experience in interventional cardiology will be invaluable as we develop our ongoing clinical and commercialization strategies of the Trilogy heart valve system for the treatment of aortic valve diseases. Moreover, his demonstrated commitment to the most critically ill cardiac patients, leadership in advancing structural heart devices, and clinical study experience make him an ideal addition to our team.”

JenaValve’s Trilogy device is a transcatheter aortic valve replacement system designed to treat patients with symptomatic, severe aortic regurgitation and symptomatic, severe aortic stenosis in high surgical risk patients. The Trilogy system received European CE Mark approval in May 2021. Trilogy received FDA Breakthrough Device designation to facilitate the review of the pivotal ALIGN-AR pivotal trial in the United States as part of the company’s premarket approval application for the device for the treatment of symptomatic, severe aortic regurgitation in high surgical risk patients, noted the company.